ClinicalTrials.gg
CompletedNCT04040816Updated Nov 5, 2021

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

A Phase 2 interventional study of SAP-001 in Gout and Hyperuricemia, sponsored by Shanton Pharma Co., Ltd.. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Shanton Pharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jan 2019, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
93rd of 149
40 · median 74
Started
2019
with 10 others
Phase 2
45 of 164
2 open now
Registered
104th of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 93rd largest by enrollment of the 149 interventional ones that give a count, is one of 11 that started in 2019, is one of 45 in phase 2, and was the 104th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients with Hyperuricemia.

Read the detailed description

This multiple dose study will include up to 4 cohorts. Each cohort will be comprised of 15 patients who will be dosed with SAP-001 or placebo once daily (QD) for 28 days. Dose escalation from Cohort 1 to Cohort 2 will occur after preliminary data are partially unblinded and safety data along with PK and PD parameters are analyzed and reviewed. Enrollment in Cohort 3 will begin after the last subject is randomized into Cohort 2.

Prior to starting enrollment into Cohort 4, a complete safety assessment of Cohorts 1, 2 and 3 will be performed to select the dose to be used in Cohort 4.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 and ≤ 75 years of age.
  2. (BMI) ≥ 19 and ≤ 42 kg/m2 at screening.
  3. sUA levels ≥ 7.5 mg/dL during screening and at check-in (Day -1).
  4. Patients must meet the American College of Rheumatology scoring criteria for the classification of primary gout (Neogi et al 2015).
  5. Patients must be able to take gout flare prophylaxis with colchicine 0.6 mg QD throughout the study as the primary method to prevent disease flare. If colchicine is not tolerated or , naproxen 250 mg BID with or without H2 antagonists will be employed as a gout flare prophylactic agent. Gout flare prophylaxis will be initiated at the Day -1 visit in patients who are sUA-lowering agent naïve. For patients that discontinue an sUA-lowering agent(s) (ie, washout from current therapy) during the screening period, gout flare prophylaxis should be initiated at the time of discontinuation of the sUA-lowering agent(s).
  6. Is a nonsmoker or light smoker (smokes fewer than 10 cigarettes per day).
  7. Female patients either will be (female patients who state they are postmenopausal should have had cessation of menses for > 1 year and have serum follicle-stimulating hormone [FSH] levels > 40 mIU/mL and serum estradiol \< 20 pg/mL); or surgically sterile (including bilateral tubal ligation, salpingectomy [with or without oophorectomy], surgical hysterectomy, or bilateral oophorectomy [with or without hysterectomy]) for at least 3 months prior to screening; or will agree to use, from the time of check-in (Day -1) until 90 days following the last dose of study drug, the following forms of : double-barrier method, hormonal contraceptives, barrier with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, oral, implantable, or injectable contraceptives, or a sterile sexual partner. All female patients, except those with documented surgical hysterectomy in medical history, will have a negative urine pregnancy test result prior to enrollment in the study.
  8. Male patients either will be surgically sterile or agree to use, from the time of check-in (Day -1) until 90 days following the last dose of study drug, the following forms of contraception: male condom with spermicide and a female partner who is sterile or agrees to use hormonal contraceptives, female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, oral, implantable, or injectable contraceptives. Male patients will refrain from sperm donation from the time of check-in (Day -1) until 90 days following the last dose of study drug.
  9. Is capable of understanding the written , provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.

    Cohorts 1 through 3:

  10. Patients who are not taking any UA-lowering medications within 2 weeks prior to the dose of study drug. Patients may discontinue sUA-lowering agents (ie, washout from current therapy) during the screening period. In the cases of a patient who must discontinue sUA-lowering agents or a patient not previously taking sUA-lowering agents during the screening period, gout flare prophylaxis should be initiated with colchicine 0.6 mg QD as the primary method to prevent disease flare and be continued during the study period. If colchicine is not tolerated or contraindicated, naproxen 250 mg BID with or without H2 antagonists will be employed as a second line gout flare prophylactic agent.

    Cohort 4:

  11. Patient has been on a stable dose of allopurinol as existing urate-lowering therapy for at least 3 months prior to Day 1.

Exclusion criteria

Exclusion Criteria:

  1. Female patient is pregnant, planning to get pregnant, or lactating/breastfeeding.
  2. Has a history or presence of CS cardiovascular, renal, pulmonary, hepatic, gallbladder or biliary tract, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, which in the investigator's opinion would not be suitable for the study.
  3. Serum creatinine level > 1.5 mg/dL and/or estimated (eGFR) ≤ 60 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Levey et al 2009; National Institute of Diabetes and Digestive and Kidney Diseases, Estimating Glomerular Filtration Rate) at screening.
  4. History of stomach or intestinal surgery (except cholecystectomy, appendectomy, and/or hernia repair will be allowed).
  5. History of prescription drug abuse, illicit drug use, or alcohol abuse according to medical history within 6 months prior to the screening visit or any alcohol use for at least 48 hours prior to dosing on Day 1.
  6. Positive test for (HIV).
  7. Positive test for virus or virus (HCV) consistent with current infection. Confirmatory tests will be allowed at the discretion of the investigator to rule out false positives.
  8. abnormal liver function test at screening or check-in (Day -1), defined as (AST) or alanine aminotransferase (ALT) > 1.5 × (ULN) or total > ULN; or a history of CS acute or chronic hepatitis (including infectious, metabolic, , genetic, ischemic, or other forms), hepatocirrhosis, or hepatic tumors.
  9. Positive screen for alcohol or drugs of abuse (except for patients with a positive drug screen if it is a result of a prescribed medication from their physician) at screening or check-in (Day -1).
  10. History of a gout flare that is resolved within 14 days prior to the first dose of study drug on Day 1 (exclusive of chronic synovitis/arthritis). If a gout flare occurs during screening, patients may be rescreened after a period of at least 14 days has passed following the flare.
  11. Has a known to URAT1 inhibitors, XOIs, or related compounds.
  12. Receipt of any other product within 30 days prior to the first dose of study drug on Day 1 or planning to take an investigational agent during the study.
  13. Use of drugs or nutrients known to significantly modulate cytochrome P450 (CYP)3A activity starting from 14 days prior to the first dose of study drug on Day 1 until EOS (any strong or moderate inhibitors or inducers of , including but not limited to the following: inhibitors such as ketoconazole, miconazole, itraconazole, fluconazole, atazanavir, erythromycin, clarithromycin, ranitidine, cimetidine, verapamil, and diltiazem; and inducers such as rifampicin, rifabutin, , carbamazepine, phenytoin, phenobarbital, and St. John's wort).
  14. Participated in strenuous exercise from 48 hours prior to check-in (Day -1) or during the study through EOS.
  15. Has donated or lost a significant volume (> 500 mL) of blood or plasma within 30 days prior to check-in (Day -1).
  16. within 5 years prior to the screening visit (excluding basal cell carcinoma).
  17. Has problems understanding the protocol requirements, instructions, study-related restrictions, and/or problems understanding the nature, scope, and potential consequences of participating in this clinical study.
  18. Is unlikely to comply with the protocol requirements, instructions, and/or study-related restrictions (eg, uncooperative attitude, unavailable for follow up, and/or improbability of completing the clinical study).

    Cohorts 1 through 3:

  19. Concomitant use of or treatment with any prescription drugs, herbal products, vitamins, minerals, and over-the-counter (OTC) medications that are known to lower sUA levels (eg, allopurinol, febuxistat, probenecid, lesinurad, and peglodicase) within 14 days prior to check-in (Day -1). Exceptions may be made on a case-by-case basis (such as chronic use of low dose aspirin) following discussion and agreement between the investigator and sponsor.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Dose A

    Dose A SAP-001 versus placebo

    Drug: SAP-001

  • Experimental
    Dose B

    Dose B SAP-001 versus placebo

    Drug: SAP-001

  • Experimental
    Dose C

    Dose C SAP-001 versus placebo

    Drug: SAP-001

  • Experimental
    Dose D (allopurinol patients)

    Dose D SAP-001 versus placebo in gout patients who remain on allopurinol

    Drug: SAP-001

Interventions

  • SAP-001 or placebo treatment in a 4:1 randomization ratio

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Assess the safety and tolerability of multiple ascending doses of oral SAP-001 over 28 days compared to placebo

    Time frame: 28 days

  2. Cmax

    Maximum observed plasma concentration

    Time frame: 28 days

  3. tmax

    Time to maximum observed plasma concentration

    Time frame: 28 days

  4. AUC0-t

    Area under the plasma concentration-time curve from time 0 to time t

    Time frame: 28 days

  5. AUC0-24h

    Area under the plasma concentration-time curve from time 0 until 24 hours postdose

    Time frame: 28 days

  6. AUC0-∞

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity

    Time frame: 28 days

  7. λz

    Apparent terminal elimination rate constant

    Time frame: 28 days

  8. t½

    Terminal elimination phase half-life

    Time frame: 28 days

  9. CL/F

    Total body clearance

    Time frame: 28 days

  10. Vz/F

    Volume of distribution

    Time frame: 28 days

  11. sUA

    Serum urate concentration, change from baseline, and percent change from baseline

    Time frame: 28 days

  12. Creatinine

    Creatinine levels, change from baseline, and percent change from baseline

    Time frame: 28 days

Secondary outcomes

  1. Urate Lowering Effect

    Assess the urate lowering effects of serum urate levels at various time points for multiple ascending doses of SAP-001 over 28 days compared to placebo

    Time frame: 28 days

  2. Inflammation markers including cytokines IL-1β, IL-6, IL-8, and TNFα

    Assess the effects of multiple ascending doses of SAP-001 on selected inflammation markers over 28 days compared to placebo

    Time frame: 28 days

07

Study locations

6 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Anaheim Clinical Trials (ACT)
    Anaheim, California 92801, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Vince & Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
  • M3 Wake Research, Inc
    Raleigh, North Carolina 27612, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Aug 2020, 19 months.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Aug 1, 2019
StartActual
Jan 1, 2019
Primary completionActual
Aug 1, 2020
CompletionActual
Aug 30, 2020
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04040816
Lead sponsor
Shanton Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Jan 1, 2019
Primary completion
Aug 1, 2020
Completion
Aug 30, 2020
Last update
Nov 5, 2021

Study contacts

Celina Cabale-Scholl, DPT, RN
study chair · Shanton Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAP-001

Start the discussion